National Clinical Guideline Centre Cost-Effectiveness Assessment for the National Institute for Health and Clinical Excellence
National Clinical Guideline Centre Cost-Effectiveness Assessment for the National Institute for Health and Clinical Excellence
复制标题
国家健康与临床卓越研究所国家临床指南中心成本效益评估
DOI：
--
复制
发表时间：
2011
影响因子：
39.2
通讯作者：
P. Laramée
中科院分区：
文献类型：
--
作者：
D. Wonderling;L. Sawyer;E. Fenu;K. Lovibond;P. Laramée
国家临床指南中心（NCGC）代表英国国家健康与临床卓越研究所（NICE）制定循证临床指南。英国卫生署已委托NICE根据临床效果和成本效益提出建议。本文介绍了如何在NCGC指南中评估和解释成本效益。六个最近的案例研究，其中考虑成本效益已通知建议以各种方式的临床指南，酒精使用障碍，慢性阻塞性肺疾病，青光眼，下尿路症状，非ST段抬高心肌梗死和不稳定型心绞痛，静脉血栓栓塞预防。在试图占成本效益的临床指南所面临的一些挑战进行了概述，以及在适应成本效益的其他设置的指导方针的一些困难。
The National Clinical Guideline Centre (NCGC) develops evidence-based clinical guidelines on behalf of the National Institute for Health and Clinical Excellence (NICE) in the United Kingdom. The U.K. Department of Health has commissioned NICE to make recommendations on the basis of both clinical effectiveness and cost-effectiveness. This article describes how cost-effectiveness is evaluated and accounted for in NCGC guidelines. Six recent case studies are presented, in which consideration of cost-effectiveness has informed recommendations in various ways for clinical guidelines on alcohol use disorders, chronic obstructive pulmonary disease, glaucoma, lower urinary tract symptoms, non-ST-segment elevation myocardial infarction and unstable angina, and venous thromboembolism prophylaxis. Some of the challenges faced in trying to account for cost-effectiveness in clinical guidelines are outlined, as well as some of the difficulties in adapting cost-effectiveness guidelines for other settings.